ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen LLC, a biotechnology company focused on developing proprietary gene-based molecular diagnostics announced today that Ann Arbor SPARK, the driving force in establishing the Ann Arbor region as a destination for business expansion, retention, and location, has approved a $250,000 investment in SensiGen from the Michigan Pre-Seed Capital Fund. The funds will be used to help SensiGen establish a new research laboratory in Ann Arbor and to accelerate development of the Company’s revolutionary AttoSense™ molecular diagnostic technology.
